Ipsen’s culture of ‘collaboration and diversity’ earns Great Place to Work certification

Ipsen Australia and New Zealand has announced its certification as a Great Place to Work in 2024, joining 11 other Ipsen offices worldwide. This achievement signifies that Ipsen is now recognised as an employer of choice in a total of 28 countries globally.

The Great Place to Work survey highlighted Ipsen Australia’s impressive scores, particularly in the areas of ‘Justice’, ‘Purpose’, ‘Camaraderie’, and ‘Intimacy’.

Julien Dagher, General Manager at Ipsen Australia and New Zealand, expressed his delight at receiving this certification and emphasised the importance of nurturing this culture moving forward.

“We are proud to have been certified as a Great Place to Work in 2024. This is an important milestone for us and a testament to the incredible culture we’ve built together,” he said.

“Thank you to everyone in the team for the collective commitment in fostering a supportive and inclusive environment where everyone can thrive and succeed.”

Régis Mulot, EVP and Chief Human Resources Officer at Ipsen, echoed this sentiment, saying “These recognitions are an immense pride for us. This achievement is a direct reflection of our incredible people, whose passion and determination make Ipsen a special place to work. We are committed to maintaining and enhancing this culture as we continue to grow and make a meaningful impact on society and the patients we serve.”

Melanie Barlow, Head of Human Resources at Ipsen Australia and New Zealand, emphasised the significance of creating supportive environments for employee growth and success.

“We believe that by creating a supportive working environment, we can further drive innovation and excellence in the work we do. Being certified as a Great Place to Work in 2024 is a testament to our commitment to creating a space where every team member feels valued, empowered, and inspired by the people around them and the work they do.

“Together, we have fostered a culture of collaboration that celebrates diversity and prioritises well-being, as we work to improve patient outcomes,” Barlow stated.

In related news, Ipsen’s Iqirvo (elafibranor) for the treatment of primary biliary cholangitis (PBC) is currently under evaluation by the TGA, while Sohonos (palovarotene) for fibrodysplasia ossificans progressiva (FOP) is on the PBAC meeting agenda for this month.

In reimagining healthcare, Health Industry Hub^TM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.